PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bioavailability

Conditions

Bioavailability

Trial Timeline

Mar 10, 2022 → May 19, 2022

NCT ID

NCT05263921

About PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir

PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir is a phase 1 stage product being developed by Pfizer for Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT05263921. Target conditions include Bioavailability.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05263921	Phase 1	Completed	Mar 10, 2022	May 19, 2022	Bioavailability

Competing Products

20 competing products in Bioavailability

See all competitors

Product	Company	Stage	Hype Score
solifenacin succinate suspension + solifenacin succinate tablet	Astellas Pharma	Phase 1	33
ASP015K	Astellas Pharma	Phase 1	33
ASP015K	Astellas Pharma	Phase 1	33
Ipragliflozin	Astellas Pharma	Phase 1	33
Hetrombopag	Jiangsu Hengrui Medicine	Phase 1	33
ABT-450/r/ABT-267	AbbVie	Phase 1	33
ABT-333	AbbVie	Phase 1	33
Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2	AstraZeneca	Phase 1	33
Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orally	AstraZeneca	Phase 1	33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single dose	AstraZeneca	Phase 1	33
selumetinib 75mg single dose	AstraZeneca	Phase 1	33
Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube	AstraZeneca	Phase 1	33
AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423	AstraZeneca	Phase 1	33
Fostamatinib + Fostamatinib + Fostamatinib + Fostamatinib	AstraZeneca	Phase 1	33
BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg	AstraZeneca	Phase 1	33
D1400147 + D14000136 + D14000137 + Epanova®	AstraZeneca	Phase 1	33
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water	AstraZeneca	Phase 1	33
NKTR-118 + Ketoconazole	AstraZeneca	Phase 1	33
TEPEZZA + EDP	Amgen	Phase 1	32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332	Pfizer	Phase 1	32

Other Products from Pfizer